Contineum Therapeutics (CTNM) Net Income towards Common Stockholders (2023 - 2026)

Contineum Therapeutics' Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$56.8 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 253.99% year-over-year to -$56.8 million; the TTM figure through Jun 2026 stood at -$127.0 million (down 164.7% YoY), while the FY2025 annual figure was -$107.8 million, down 223.05% from the prior year.
• Net Income towards Common Stockholders for Q2 2026 stood at -$56.8 million, down from -$41.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $41.6 million in Q2 2023, with the low at -$56.8 million in Q2 2026.
• The 4-year median for Net Income towards Common Stockholders is -$11.2 million (2023), against an average of -$12.4 million.
• The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders jumped 53.46% in 2024, then tumbled 253.99% in 2026.
• Contineum Therapeutics' Net Income towards Common Stockholders stood at -$12.2 million in 2023, then surged by 53.46% to -$5.7 million in 2024, then plunged by 180.95% to -$16.0 million in 2025, then tumbled by 255.81% to -$56.8 million in 2026.
• Business Quant data shows CTNM's Net Income towards Common Stockholders at -$56.8 million in Q2 2026, -$41.5 million in Q1 2026, and -$16.0 million in Q4 2025.